Femasys partners with MES to launch sperm analysis kit

ATLANTA - Femasys Inc. (NASDAQ:FEMY), a micro-cap medical device company with a market capitalization of $15 million, announced Monday a partnership with Medical Electronic Systems LLC (MES) to provide advanced sperm analysis technology through its new FemSperm Analysis Kit.

The new product completes Femasys’ FemSperm product family, which includes the Setup Kit and Insemination Prep Kit. The complete system enables gynecologists to perform in-office sperm preparation and analysis for use with FemaSeed Intratubal Insemination, the company’s first-step infertility treatment.

"The launch of the FemSperm Analysis Kit advances our mission to deliver innovative reproductive care that is more accessible and affordable for the millions of women facing infertility," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. According to InvestingPro data, the company has achieved impressive revenue growth of 98.61% over the last twelve months, though currently trades below its Fair Value.

Eric Carver, President of Medical Electronic Systems LLC, stated that the company’s "industry-leading semen analysis technology powers the FemSperm Analysis Kit, delivering accurate, efficient, and standardized assessment of key sperm parameters."

The FemSperm product family allows gynecologists to offer FemaSeed Intratubal Insemination directly within their practices. FemaSeed delivers sperm to the fallopian tube and, according to the company’s pivotal trial, achieved more than double the pregnancy rates of intrauterine insemination (IUI) in cases of low male sperm count.

Femasys manufactures fertility and non-surgical permanent birth control products. Its portfolio includes FemaSeed Intratubal Insemination, FemVue for fallopian tube assessment, and FemBloc permanent birth control, which received regulatory approval in Europe, the United Kingdom, and New Zealand in 2025. While maintaining a strong gross profit margin of 65.09%, InvestingPro analysis reveals 14 additional key insights about the company’s financial health and market position, available to subscribers.

The information in this article is based on a company press release statement.

In other recent news, Femasys Inc. announced the pricing of an underwritten public offering expected to raise approximately $8 million in gross proceeds. The offering includes 10,434,586 shares of common stock and pre-funded warrants to purchase up to 11,750,000 shares, priced at $0.36 per share. Additionally, Femasys received UK regulatory approval for its FemBloc Permanent Birth Control system, marking a significant step in its European commercialization strategy. The company also secured its first European commercial order for the FemBloc system, valued at approximately $400,000 USD from distribution partners in Spain. This order signifies Femasys’ initial commercial entry into Europe. Furthermore, Femasys received a notification from Nasdaq regarding noncompliance with the minimum bid price requirement, as its stock closed below $1.00 per share for 30 consecutive business days. The company has been given a 180-day grace period to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.